Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2204 | Low-Carbohydrate Diet Wiki | 0.50 |
| drug2358 | Metformin XR Wiki | 0.50 |
| drug2471 | NBT-NM108 Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018149 | Glucose Intolerance NIH | 0.58 |
| D006943 | Hyperglycemia NIH | 0.35 |
| D050197 | Atherosclerosis NIH | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011998 | Postprandial hyperglycemia HPO | 0.35 |
| HP:0000818 | Abnormality of the endocrine system HPO | 0.35 |
| HP:0002621 | Atherosclerosis HPO | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000819 | Diabetes mellitus HPO | 0.09 |
Navigate: Correlations HPO
There are 4 clinical trials
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.
Description: The primary outcome measure is the time to first occurrence of death, non-fatal myocardial infarction or stroke, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or coronary revascularization driven by acute or progressive symptoms.
Measure: Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization Time: through study completion, an average of 4.5 yearsDescription: Time to first occurrence of death, myocardial infarction, or stroke Time to first occurrence of a primary endpoint event, peripheral arterial disease event, or hospitalization for congestive heart failure Cumulative incidence of all components of the primary endpoint, including recurrent or multiple events in the same participant Cumulative incidence and time to first occurrence of each component of the primary outcome measure, peripheral arterial disease events, and hospitalization for congestive heart failure
Measure: Time in days to Cardiovascular Outcomes Time: through study completion, an average of 4.5 yearsDescription: Time to new or recurrent diagnosis of a malignancy or death from a malignancy
Measure: Time in days to Oncologic Outcome Time: through study completion, an average of 4.5 yearsDescription: Time to new diagnosis of type 2 diabetes (ADA criteria)
Measure: Time in days to Diabetes Outcome Time: through study completion, an average of 4.5 yearsThe proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.
Description: Based on 10-year cardiovascular disease risk assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score
Measure: Change in estimated cardiovascular disease risk Time: Baseline and six monthsThis open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat early-stage suspected or confirmed COVID-19 in patients with type 2 diabetes mellitus (T2DM) or prediabetes.
Description: Discontinuation of home isolation status
Measure: Outcome of COVID-19 related illnesses Time: At days 0, 14, 28, and 56Description: Hospitalization status
Measure: Outcome of COVID-19 related illnesses Time: At days 0, 14, 28, and 56Description: Deaths
Measure: Outcome of COVID-19 related illnesses Time: At days 0, 14, 28, and 56Description: All vital signs are within the normal range for at least 24 h, including body temperature 36.5-37.5°C (97.7-99.5°F), pulse rate <90/min, respiratory rate 12-16/min and oxygen saturation level at 95-100%
Measure: Proportion of participants who have complete resolution of all objective symptoms Time: At days 0, 14, 28, and 56Description: Absence of all COVID-19-like symptoms listed by CDC (updated May 13, 2020) for at least 24 h, including fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea
Measure: Proportion of participants who have complete resolution of subjective symptoms Time: At days 0, 14, 28, and 56DPPFit is a Healthy Lifestyle Intervention designed to reformat the effective strategies of the Diabetes Prevention Program (NDPP) into a tool for use in a primary care setting. DPPFit is a 16-week technology-based intervention for diabetes prevention. In keeping with the National DPP educational sessions, the intervention weeks follow the order and presentation of the N-DPP 16 session topics. The goal is to develop a pragmatic translation of the DPP that is effective in the real-world setting of primary care clinic. The hope is that in doing so, those at risk of developing type II diabetes mellitus will have evidenced-based prevention methods at their disposal.
Description: Weight Loss by % of Body Weight Loss, by # of Participants losing 5% and 7% of Body Weight
Measure: Weight Loss Time: 12 MonthsDescription: Increase in PA days/week, Increase > 10% of PA, Kcal/week
Measure: Physical Activity Time: 6 monthsDescription: Decrease in Sedentary Time, Mins/day
Measure: Inactivity Time: 6 monthsDescription: MOS SF-20 / MOS Social Support Scale
Measure: Health Related Quality of Life Time: 6 months /Description: Reduction in % of HbA1c at 1 year follow-up
Measure: Hemoglobin A1c Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports